Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2102 Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study

Introduction: TGR0 >4%/month was associated with shorter progression-free survival (PFS) in patients (pts) treated with lanreotide in the CLARINET study. Impact of TGR0 in pts treated with other systemic therapies (ST) and with Ki67>10% is unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Crona J

Authors: Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, TGR, RECIST, Neuroendocrine Tumor,

#2053 Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients’ Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study

Introduction: TGR (% change in tumour volume per month (%/m)) is postulated to be an early radiological biomarker to overcome limitations of RECIST in NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lamarca A

Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, response, progression-free survival, follow-up, neuroendocrine tumor, prognosis, TGR, RECIST, radiology,

#1606 Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis

Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Van Fraeyenhove F, Meireson N, Mattelaer C, De Droogh E, Galdermans D,

Keywords: non-functional lung neuroendocrine tumors, lanreotide, tumor growth, case-series,

#1475 Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data

Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Dromain C

Authors: Caplin M, Pavel M, Ruszniewski P, Liyanage N, Massien C,

Keywords: TGR, PFS,